Cargando…
The beneficial effect of Zinc(II) on low-dose chemotherapeutic sensitivity involves p53 activation in wild-type p53-carrying colorectal cancer cells
BACKGROUND: Activation of wild-type p53 in response to genotoxic stress occurs through different mechanisms including protein conformation, posttranslational modifications, and nuclear localization, leading to DNA binding to sequence-specific promoters. Zinc ion plays a crucial role in stabilizing p...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4546314/ https://www.ncbi.nlm.nih.gov/pubmed/26297485 http://dx.doi.org/10.1186/s13046-015-0206-x |
_version_ | 1782386901547745280 |
---|---|
author | Garufi, Alessia Ubertini, Valentina Mancini, Francesca D’Orazi, Valerio Baldari, Silvia Moretti, Fabiola Bossi, Gianluca D’Orazi, Gabriella |
author_facet | Garufi, Alessia Ubertini, Valentina Mancini, Francesca D’Orazi, Valerio Baldari, Silvia Moretti, Fabiola Bossi, Gianluca D’Orazi, Gabriella |
author_sort | Garufi, Alessia |
collection | PubMed |
description | BACKGROUND: Activation of wild-type p53 in response to genotoxic stress occurs through different mechanisms including protein conformation, posttranslational modifications, and nuclear localization, leading to DNA binding to sequence-specific promoters. Zinc ion plays a crucial role in stabilizing p53/DNA binding to induce canonical target genes. Mutant p53 proteins undergo protein misfolding that can be counteracted by zinc. However, whether zinc supplementation might have a beneficial antitumor effect in wild-type p53-carrying cells in combination with drugs, has not been addressed so far. METHODS: In this study we compared the effect of two antitumor treatments: on the one hand wild-type p53-carrying colon cancer cells were treated with low and high doses of chemotherapeutic agent Adriamycin and, on the other hand, Adriamycin was used in combination with ZnCl(2). Biochemical and molecular analyses were applied to evaluate p53 activity and biological outcomes in this setting. Finally, the effect of the different combination treatments were applied to assess tumor growth in vivo in tumor xenografts. RESULTS: We found that low-dose Adriamycin did not induce p53 activation in wtp53-carrying colon cancer cells, unless in combination with ZnCl(2). Mechanistically, ZnCl(2) was a key determinant in inducing wtp53/DNA binding and transactivation of target genes in response to low-dose Adriamycin that used alone did not achieve such effects. Finally, in vivo studies, in a model of wtp53 colon cancer xenograft, show that low-dose Adriamycin did not induce tumor regression unless in combination with ZnCl(2) that activated endogenous wtp53. CONCLUSIONS: These results provide evidence that ZnCl(2) might be a valuable adjuvant in chemotherapeutic regimens of colorectal cancer harboring wild-type p53, able to both activate p53 and reduce the amount of drugs for antitumor purposes. |
format | Online Article Text |
id | pubmed-4546314 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-45463142015-08-23 The beneficial effect of Zinc(II) on low-dose chemotherapeutic sensitivity involves p53 activation in wild-type p53-carrying colorectal cancer cells Garufi, Alessia Ubertini, Valentina Mancini, Francesca D’Orazi, Valerio Baldari, Silvia Moretti, Fabiola Bossi, Gianluca D’Orazi, Gabriella J Exp Clin Cancer Res Research BACKGROUND: Activation of wild-type p53 in response to genotoxic stress occurs through different mechanisms including protein conformation, posttranslational modifications, and nuclear localization, leading to DNA binding to sequence-specific promoters. Zinc ion plays a crucial role in stabilizing p53/DNA binding to induce canonical target genes. Mutant p53 proteins undergo protein misfolding that can be counteracted by zinc. However, whether zinc supplementation might have a beneficial antitumor effect in wild-type p53-carrying cells in combination with drugs, has not been addressed so far. METHODS: In this study we compared the effect of two antitumor treatments: on the one hand wild-type p53-carrying colon cancer cells were treated with low and high doses of chemotherapeutic agent Adriamycin and, on the other hand, Adriamycin was used in combination with ZnCl(2). Biochemical and molecular analyses were applied to evaluate p53 activity and biological outcomes in this setting. Finally, the effect of the different combination treatments were applied to assess tumor growth in vivo in tumor xenografts. RESULTS: We found that low-dose Adriamycin did not induce p53 activation in wtp53-carrying colon cancer cells, unless in combination with ZnCl(2). Mechanistically, ZnCl(2) was a key determinant in inducing wtp53/DNA binding and transactivation of target genes in response to low-dose Adriamycin that used alone did not achieve such effects. Finally, in vivo studies, in a model of wtp53 colon cancer xenograft, show that low-dose Adriamycin did not induce tumor regression unless in combination with ZnCl(2) that activated endogenous wtp53. CONCLUSIONS: These results provide evidence that ZnCl(2) might be a valuable adjuvant in chemotherapeutic regimens of colorectal cancer harboring wild-type p53, able to both activate p53 and reduce the amount of drugs for antitumor purposes. BioMed Central 2015-08-22 /pmc/articles/PMC4546314/ /pubmed/26297485 http://dx.doi.org/10.1186/s13046-015-0206-x Text en © Garufi et al. 2015 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Garufi, Alessia Ubertini, Valentina Mancini, Francesca D’Orazi, Valerio Baldari, Silvia Moretti, Fabiola Bossi, Gianluca D’Orazi, Gabriella The beneficial effect of Zinc(II) on low-dose chemotherapeutic sensitivity involves p53 activation in wild-type p53-carrying colorectal cancer cells |
title | The beneficial effect of Zinc(II) on low-dose chemotherapeutic sensitivity involves p53 activation in wild-type p53-carrying colorectal cancer cells |
title_full | The beneficial effect of Zinc(II) on low-dose chemotherapeutic sensitivity involves p53 activation in wild-type p53-carrying colorectal cancer cells |
title_fullStr | The beneficial effect of Zinc(II) on low-dose chemotherapeutic sensitivity involves p53 activation in wild-type p53-carrying colorectal cancer cells |
title_full_unstemmed | The beneficial effect of Zinc(II) on low-dose chemotherapeutic sensitivity involves p53 activation in wild-type p53-carrying colorectal cancer cells |
title_short | The beneficial effect of Zinc(II) on low-dose chemotherapeutic sensitivity involves p53 activation in wild-type p53-carrying colorectal cancer cells |
title_sort | beneficial effect of zinc(ii) on low-dose chemotherapeutic sensitivity involves p53 activation in wild-type p53-carrying colorectal cancer cells |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4546314/ https://www.ncbi.nlm.nih.gov/pubmed/26297485 http://dx.doi.org/10.1186/s13046-015-0206-x |
work_keys_str_mv | AT garufialessia thebeneficialeffectofzinciionlowdosechemotherapeuticsensitivityinvolvesp53activationinwildtypep53carryingcolorectalcancercells AT ubertinivalentina thebeneficialeffectofzinciionlowdosechemotherapeuticsensitivityinvolvesp53activationinwildtypep53carryingcolorectalcancercells AT mancinifrancesca thebeneficialeffectofzinciionlowdosechemotherapeuticsensitivityinvolvesp53activationinwildtypep53carryingcolorectalcancercells AT dorazivalerio thebeneficialeffectofzinciionlowdosechemotherapeuticsensitivityinvolvesp53activationinwildtypep53carryingcolorectalcancercells AT baldarisilvia thebeneficialeffectofzinciionlowdosechemotherapeuticsensitivityinvolvesp53activationinwildtypep53carryingcolorectalcancercells AT morettifabiola thebeneficialeffectofzinciionlowdosechemotherapeuticsensitivityinvolvesp53activationinwildtypep53carryingcolorectalcancercells AT bossigianluca thebeneficialeffectofzinciionlowdosechemotherapeuticsensitivityinvolvesp53activationinwildtypep53carryingcolorectalcancercells AT dorazigabriella thebeneficialeffectofzinciionlowdosechemotherapeuticsensitivityinvolvesp53activationinwildtypep53carryingcolorectalcancercells AT garufialessia beneficialeffectofzinciionlowdosechemotherapeuticsensitivityinvolvesp53activationinwildtypep53carryingcolorectalcancercells AT ubertinivalentina beneficialeffectofzinciionlowdosechemotherapeuticsensitivityinvolvesp53activationinwildtypep53carryingcolorectalcancercells AT mancinifrancesca beneficialeffectofzinciionlowdosechemotherapeuticsensitivityinvolvesp53activationinwildtypep53carryingcolorectalcancercells AT dorazivalerio beneficialeffectofzinciionlowdosechemotherapeuticsensitivityinvolvesp53activationinwildtypep53carryingcolorectalcancercells AT baldarisilvia beneficialeffectofzinciionlowdosechemotherapeuticsensitivityinvolvesp53activationinwildtypep53carryingcolorectalcancercells AT morettifabiola beneficialeffectofzinciionlowdosechemotherapeuticsensitivityinvolvesp53activationinwildtypep53carryingcolorectalcancercells AT bossigianluca beneficialeffectofzinciionlowdosechemotherapeuticsensitivityinvolvesp53activationinwildtypep53carryingcolorectalcancercells AT dorazigabriella beneficialeffectofzinciionlowdosechemotherapeuticsensitivityinvolvesp53activationinwildtypep53carryingcolorectalcancercells |